new technologies

AI, ML, RPA & more

Not every new technology in the market will have commercial value for software companies or enterprises. The B2B market requires technologies to be mature enough to last through time and provide value. We investigate the commercial viability of new promising technologies.

We also have events and workshops for clients focusing solely on innovation. Innovation is never an afterthought but requires dedication so you can entirely focus on creating an experiment based on customer or market requirements.

We found Yonder to be the perfect complement to our team. They were highly skilled in organizing and driving the prototype process and were well-versed in the technologies needed to create a successful prototype. They listened to our ideas and blended their concepts with ours in a skillful manner. At every stage of the process, the Yonder team offered valuable recommendations on the direction that should be undertaken, and they were flexible and understanding when we modified our design.

Kerry Lynn,
Executive Vice President @Syscon

new technologies services

Artificial Intelligence - AI

Gartner regards AI and ML as one of the five most important technologies for this decade. Yet most endeavors don’t end up in production. We have services and workshops to help you experiment and find your approach to AI.
Machine Learning - ML

ML is considered part of AI and can be defined broadly as the capability of a machine to imitate intelligent human behavior.
Robotic process automation RPA

RPA can help automate repetitive tasks, which usually take a lot of time and are not very inspiring. We have investigated several interesting tools on the market, each with value, but based on your specific situation, one may fit your needs better.

Artificial Intelligence - AI
Machine Learning - ML
Robotic process automation RPA

It is a kick-start of a project, in this case for the topic Smart Formulary. We are in the first phase of the project, and during the hackathon, we gain insight into the technical feasibility. We can then make a better estimate of the development effort and costs involved.

Martijn Ivens,
Manager Innovation @PharmaPartners GPs